Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals Conference Call to discuss 9-month results from the HELIOS-A Phase III study. (Operator Instructions) Please be advised that this call is being taped at the company's request. I would now like to turn the call over to the company.
Good afternoon. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are John Maraganore, Chief Executive Officer; Akshay Vaishnaw, President of R&D; and Yvonne Greenstreet, President and Chief Operating Officer. Also on the line and available for Q&A are Tolga Tanguler, Chief Commercial Officer; Pushkal Garg, Chief Medical Officer; and Rena Denoncourt, Vice President of Vutrisiran and Program Leader.
For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
